guest ::
| Home > Publications database > Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial > print |
| Home > Publications database > Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial > print |
| 001 | 863990 | ||
| 005 | 20210130002359.0 | ||
| 024 | 7 | _ | |a 10.1007/s11060-019-03246-4 |2 doi |
| 024 | 7 | _ | |a 0167-594X |2 ISSN |
| 024 | 7 | _ | |a 0167-594x |2 ISSN |
| 024 | 7 | _ | |a 1573-7373 |2 ISSN |
| 024 | 7 | _ | |a pmid:31325144 |2 pmid |
| 024 | 7 | _ | |a WOS:000487899900008 |2 WOS |
| 024 | 7 | _ | |a altmetric:67749391 |2 altmetric |
| 037 | _ | _ | |a FZJ-2019-03906 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kebir, Sied |0 0000-0002-0678-5852 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial |
| 260 | _ | _ | |a Dordrecht [u.a.] |c 2019 |b Springer Science + Business Media B.V |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1570004428_15601 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a PurposeThe phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ). To identify subpopulations with a particularly favorable course, we assessed the prognostic potential of magnetic resonance imaging (MRI) markers before treatment onset.MethodsMRIs at baseline (before treatment onset) were analyzed for T1-hyperintense and diffusion-restricted lesions; as well as the presence of both hyperintense and diffusion-restricted (double positive) lesions. The MRI findings were correlated with overall and progression-free survival.ResultsMRI scans were evaluable in 71% of the GLARIUS modified intention-to-treat population (n = 121 of 170; 88 patients in the BEV/IRI arm, and 33 patients in the TMZ control arm). Diffusion-restricted and T1 hyperintense lesions were present in 60% and 65% of patients in BEV/IRI arm, while 57% and 63% were found in the TMZ arm, respectively. Double positive lesions were found in 37% of BEV/IRI patients and in 39% of TMZ patients. Neither the presence of T1-hyperintense, diffusion-restricted lesions, nor double positive lesions were associated with improved survival.ConclusionsBaseline T1-hyperintense and diffusion-restricted lesions are not suitable to predict progression-free or overall survival of patients treated with bevacizumab/irinotecan or temozolomide. |
| 536 | _ | _ | |a 572 - (Dys-)function and Plasticity (POF3-572) |0 G:(DE-HGF)POF3-572 |c POF3-572 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Schaub, Christina |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Junold, Nina |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Hattingen, Elke |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Schäfer, Niklas |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Steinbach, Joachim P. |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Weyerbrock, Astrid |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Hau, Peter |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Goldbrunner, Roland |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 9 |
| 700 | 1 | _ | |a Weller, Johannes |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Mack, Frederic |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Tzaridis, Theophilos |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Bähr, Oliver |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Seidel, Clemens |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Schlegel, Uwe |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Schmidt-Graf, Friederike |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Rohde, Veit |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Borchers, Christian |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Tabatabai, Ghazaleh |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Hänel, Mathias |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Sabel, Michael |0 P:(DE-Juel1)165921 |b 21 |
| 700 | 1 | _ | |a Gerlach, Rüdiger |0 P:(DE-HGF)0 |b 22 |
| 700 | 1 | _ | |a Krex, Dietmar |0 P:(DE-HGF)0 |b 23 |
| 700 | 1 | _ | |a Belka, Claus |0 P:(DE-HGF)0 |b 24 |
| 700 | 1 | _ | |a Vatter, Hartmut |0 P:(DE-HGF)0 |b 25 |
| 700 | 1 | _ | |a Proescholdt, Martin |0 P:(DE-HGF)0 |b 26 |
| 700 | 1 | _ | |a Glas, Martin |0 P:(DE-HGF)0 |b 27 |
| 700 | 1 | _ | |a Herrlinger, Ulrich |0 P:(DE-HGF)0 |b 28 |
| 773 | _ | _ | |a 10.1007/s11060-019-03246-4 |0 PERI:(DE-600)2007293-4 |n 3 |p 501-509 |t Journal of neuro-oncology |v 144 |y 2019 |x 1573-7373 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/863990/files/Kebir2019_Article_BaselineT1HyperintenseAndDiffu.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/863990/files/Kebir2019_Article_BaselineT1HyperintenseAndDiffu.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:863990 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEURO-ONCOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|